Sort by
Dysbiosis-NK Cell Crosstalk in Pancreatic Cancer: Toward a Unified Biomarker Signature for Improved Clinical Outcomes
Sara Fanijavadi,
Lars Henrik Jensen
Posted: 21 December 2024
A Window to New Insights on Progression Independent of Relapse Activity in Multiple Sclerosis: Role of Therapies and Current Perspective
Tommaso Guerra,
Pietro Iaffaldano
Posted: 20 December 2024
Central Serous Chorioretinopathy in Endometriosis Treatment with Progestogen: A Metabolic Understanding
Francesco Chiara,
Sarah Allegra,
Maura Caudana,
Jacopo Mula,
Davide Turco,
Simona Liuzzi,
Maria Paola Puccinelli,
Giulio Mengozzi,
Silvia De Francia
Posted: 20 December 2024
Functional and Structural Changes in the Inner Ear and Cochlear Hair Cell Loss Induced by Hypergravity
Jin Sil Choi,
Kyu-Sung Kim,
Hyun Ji Kim
Posted: 20 December 2024
Formation of Mitochondrial Dysfunction of Nerve Cells in Cerebral Ischemia and Possibilities of Pharmacological Correction
Igor Belenichev,
Olena Popazova,
Nina Bukhtiyarova,
Victor Ryzhenko,
Sergii V. Pavlov,
Elina Suprun,
Valentyn Oksenych,
Oleksandr Kamyshnyi
Posted: 20 December 2024
Comparative Transcriptomics of Portuguese and Turkish Behçet Syndrome Patients: Are We Looking at the Same Behçet?
Tulin Isik,
Seda Tasir,
Abdulfettah Zolkhfan,
Cagdas Sahap Oygur,
Ali Kemal Oguz
Posted: 20 December 2024
Investigating the Measurement Precision of the Montreal Cognitive Assessment (MoCA) for Cognitive Screening in Parkinson's Disease Through Item Response Theory
Pedro Renato de Paula Brandão,
Danilo Assis Pereira,
Brenda Hanae Bentes Koshimoto,
Vanderci Borges,
Henrique Ballalai Ferraz,
Artur Francisco Schumacher-Schuh,
Carlos Roberto de Mello Rieder,
Maira Rozenfeld Olchik,
Ignacio F. Mata,
Vitor Tumas
Posted: 20 December 2024
Population-Level SARS-CoV-2 Rt‒pcr Cycle Threshold Values and Their Relationships with COVID‒19 Transmission and Outcome Metrics: A Time Series Analysis Across Pandemic Years
Judith Carolina De Arcos-Jiménez,
Ernestina Quintero-Salgado,
Pedro Martínez-Ayala,
Gustavo Rosales-Chavez,
Roberto Damian-Negrete,
Oscar Francisco Fernandez-Diaz,
Mariana Del Rocio Ruiz-Briseño,
Rosendo Lopez-Romo,
Patricia Noemi Vargas-Becerra,
Ruth Rodríguez-Montaño
Posted: 20 December 2024
Automated Age Estimation from OPG images and Patient Records using Deep Feature Extraction and Modified Genetic-Random Forest
Gulfem Ozlu Ucan,
Omar Abboosh Hussein Gwassi,
Burak Kerem Apaydin,
Bahadir Ucan
Posted: 20 December 2024
ELQ-316 Enhances the Efficacy of Buparvaquone and Imidocarb in Controlling the In Vitro Growth of Babesia bigemina
Natalia M. Cardillo,
Nicolas F. Villarino,
Paul A. Lacy,
Joseph S. Doggett,
Michael K. Riscoe,
Carlos E. Suarez,
Massaro W. Ueti,
Chung J. Chungwon
Background/Objectives: B. bigemina is a highly pathogenic and widely distributed tick-borne disease parasite responsible for bovine babesiosis. The development of effective and safe therapies is urgently needed for global disease control. The aim of this study was to compare the effects of endochin-like quinolone (ELQ316), buparvaquone (BPQ), imidocarb (ID), and the combinations of ID + ELQ-316 and BPQ + ELQ-316, on in vitro survival of B. bigemina. Methods: Parasites at a starting parasitemia level of 2%, were incubated with each single drug and combination of drugs, ranging from 25 to 1200 nM of concentration over four consecutive days. The inhibitory concentration 50% (IC50%) and 99% (IC99%) were estimated. Parasitemia levels were evaluated daily using microscopic examination. Data were statistically compared using the non-parametrical KruskallWallis test. Results: All drugs tested significantly inhibited (p<0.05) the growth of B. bigemina at 2% parasitemia. The combination of ID + ELQ-316 exhibited lower mean IC50% (9.2); confidence interval 95% (8.7 – 9.9) than ID (IC50%: 61.5; confidence interval 95%: 59.54 - 63.46), ELQ-316 (IC50%: 48.10; confidence interval 95%: 42.76 – 58.83), BPQ (IC50%: 44.66; confidence interval 95%: 43.56 – 45.81), and BPQ + ELQ-316 (IC50%: 27.59; confidence interval: N/A). Parasites were no longer viable in cultures treated with the BPQ + ELQ-316 combination, as well as with BPQ alone at a concentration of 1200 nM, on days 2 and 3 of treatment, respectively.; Conclusions: BPQ and ID increase the babesiacidal effect of ELQ-316. The efficacy of these combinations deserves to be evaluated in vivo, which could lead to a promising and safer treatment option against B. bigemina.
Background/Objectives: B. bigemina is a highly pathogenic and widely distributed tick-borne disease parasite responsible for bovine babesiosis. The development of effective and safe therapies is urgently needed for global disease control. The aim of this study was to compare the effects of endochin-like quinolone (ELQ316), buparvaquone (BPQ), imidocarb (ID), and the combinations of ID + ELQ-316 and BPQ + ELQ-316, on in vitro survival of B. bigemina. Methods: Parasites at a starting parasitemia level of 2%, were incubated with each single drug and combination of drugs, ranging from 25 to 1200 nM of concentration over four consecutive days. The inhibitory concentration 50% (IC50%) and 99% (IC99%) were estimated. Parasitemia levels were evaluated daily using microscopic examination. Data were statistically compared using the non-parametrical KruskallWallis test. Results: All drugs tested significantly inhibited (p<0.05) the growth of B. bigemina at 2% parasitemia. The combination of ID + ELQ-316 exhibited lower mean IC50% (9.2); confidence interval 95% (8.7 – 9.9) than ID (IC50%: 61.5; confidence interval 95%: 59.54 - 63.46), ELQ-316 (IC50%: 48.10; confidence interval 95%: 42.76 – 58.83), BPQ (IC50%: 44.66; confidence interval 95%: 43.56 – 45.81), and BPQ + ELQ-316 (IC50%: 27.59; confidence interval: N/A). Parasites were no longer viable in cultures treated with the BPQ + ELQ-316 combination, as well as with BPQ alone at a concentration of 1200 nM, on days 2 and 3 of treatment, respectively.; Conclusions: BPQ and ID increase the babesiacidal effect of ELQ-316. The efficacy of these combinations deserves to be evaluated in vivo, which could lead to a promising and safer treatment option against B. bigemina.
Posted: 20 December 2024
of 1,396